- Provides expertise in high-growth therapeutic areas to pharmaceutical and
- Aggressive acquisition strategy over the last year
BEVERLY HILLS, Calif., July 9 /PRNewswire/ -- Worldwide Clinical Trials, Inc.("WCT"), formed by Dr. Neal R. Cutler and a team of scientists, today reached a milestone in establishing itself as a premier global contract research organization with the announcement that it has closed the acquisition of MediQuest, a contract research organization providing specialized clinical development services to biopharmaceutical companies. The MediQuest acquisition was the most recent of five acquisitions made by WCT over the last year including Evidence Clinical and Pharmaceutical Research LLC, Clinical Studies Management Group, Inc., Nottingham Clinical Research Limited and CEDRA Corporation. The five acquisitions extend WCT's global footprint to more than 30 countries.
WCT is a leading therapeutically focused contract research organization that applies deep therapeutic expertise to help customers achieve their drug development goals. WCT provides clinical consulting and Phase I-IV drug development services -- including clinical trial design, clinical operations, data management, biostatistics, medical affairs, safety/pharmacovigilance, Electronic Data Capture and Interactive Voice Response System technologies, regulatory affairs, quality assurance bioanalytical services (LC-MS-MS, ligand binding, biomarkers), and pharmacokinetics -- for global pharma, specialty pharma and biotech companies.
Formed in 2007 by Dr. Cutler in partnership with The Jordan Company, a
leading private equity firm, the company focuses on complex, high-growth
therapeutic areas with primary expertise in central nervous system, and
cardiovascular disease, along with significant experience in chronic
inflammatory disease, metabolic / endocrinology and oncology. As expertise
in these areas cont
|SOURCE Worldwide Clinical Trials, Inc.|
Copyright©2008 PR Newswire.
All rights reserved